Skip to main content
Citadel Group logo

Citadel Group — Investor Relations & Filings

Ticker · CGL ISIN · AU000000CGL3 LEI · 213800FIHTDHRZIC4882 ASX Financial and insurance activities
Open in API
Filings indexed 2,090 across all filing types
Latest filing 2023-04-04 Regulatory Filings
Country AU Australia
Listing ASX CGL

About Citadel Group

https://www.citadelgroup.com.au/

Citadel Group is a software and technology company specializing in secure enterprise information management for complex environments. The firm develops and delivers software applications, digital platforms, managed services, and IT solutions. It primarily serves government departments and large corporate clients, with a focus on managing system-critical data. The company also provides solutions for the healthcare sector aimed at improving patient outcomes. The organization has evolved and now operates under the name Citadel Edge.

Recent filings

Filing Released Lang Actions
Form 8.3 - Horizon Therapeutics plc
Regulatory Filings Classification · 95% confidence The document is a 'Form 8.3' disclosure, which is a standard regulatory filing required under the Irish Takeover Panel Act. It details shareholdings and dealings by a person with interests in relevant securities representing 1% or more of an offeror or offeree (in this case, Horizon Therapeutics PLC). This type of disclosure is a specific regulatory requirement for transparency during takeover situations and is filed via a Regulatory Information Service (RNS). It does not fit into categories like M&A activity (which are usually company-issued announcements) or major shareholding notifications (which are typically for 3%+ thresholds), making 'RNS' the most appropriate classification for this regulatory disclosure.
2023-04-04 English
Form 8.3 - Horizon Therapeutics plc
Major Shareholding Notification Classification · 96% confidence The document is a 'Form 8.3' filing, which is a standard regulatory disclosure required under the Irish Takeover Panel Act. It details the interests and short positions of a person (Citadel Group) in the relevant securities of an offeror/offeree (Horizon Therapeutics PLC). This type of disclosure is a regulatory requirement for major shareholders or parties involved in takeover situations to report their positions and dealings. Since it does not fit into the specific categories of M&A activity (which usually refers to the company's own announcements) or director dealings, and is a formal regulatory disclosure, it is best classified as a Regulatory Filing (RNS).
2023-04-03 English
Form 8.3 - Horizon Therapeutics plc
Regulatory Filings Classification · 100% confidence The document is a 'Form 8.3' disclosure, which is a standard regulatory filing required under the Irish Takeover Panel Act. It details the opening position and dealings in relevant securities by a person with interests representing 1% or more in a company involved in a takeover (Horizon Therapeutics PLC). This type of disclosure is a specific regulatory requirement for transparency during M&A activity and does not fit into the other categories like M&A announcements (TAR) or director dealings (DIRS). Therefore, it is classified as a Regulatory Filing (RNS).
2023-03-31 English
Form 8.3 - Horizon Therapeutics plc
Major Shareholding Notification Classification · 100% confidence The document is a 'Form 8.3' disclosure filed under the Irish Takeover Panel rules. This form is used by persons with interests in relevant securities representing 1% or more to disclose their positions and dealings in the context of a takeover offer. This falls under the category of 'Major Shareholding Notification' (MRQ) as it reports significant share ownership levels and changes therein, which is the standard classification for Rule 8.3 disclosures in financial databases.
2023-03-30 English
Form 8.3 - Horizon Therapeutics plc
Regulatory Filings Classification · 98% confidence The document is a 'Form 8.3' disclosure filed under the Irish Takeover Panel rules. This form is used by persons with interests in relevant securities representing 1% or more to disclose their positions and dealings in the context of a takeover offer. While it involves share dealings, it is specifically a regulatory disclosure required by takeover rules rather than a standard director's dealing or a company's own share buyback. Given the specific nature of the Irish Takeover Panel disclosure, it falls under the 'Major Shareholding Notification' category as it reports significant ownership levels and changes therein during a takeover process.
2023-03-29 English
Form 8.3 - Horizon Therapeutics plc
Major Shareholding Notification Classification · 100% confidence The document is a 'Form 8.3' disclosure, which is a standard regulatory filing required under the Irish Takeover Panel Act. It details the opening position and specific dealings in the securities of an offeror/offeree (Horizon Therapeutics PLC) by a major shareholder (Citadel Group). This type of document is a mandatory regulatory disclosure regarding shareholding interests and transactions during a takeover period, fitting the 'Major Shareholding Notification' category.
2023-03-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.